Exchange: OTC·Updated 04:08 PM EDT

RHHBY News

News
all
press releases
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down
BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.
Zacks
More News
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
Zacks
The Zacks Analyst Blog Highlights Berkshire, Roche Holding, RTX, The Eastern and AmeriServ
Berkshire Hathaway, Roche and RTX headline Zacks??? latest stock reports, with growth drivers, catalysts and key risks in focus.
Zacks
Top Stock Reports for Berkshire Hathaway, Roche & RTX
Berkshire Hathaway, Roche and RTX headline today's research, with earnings drivers, growth catalysts and risks shaping their outlooks.
Zacks
Can Keytruda Sustain Merck's Growth in the Second Half of 2026?
MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.
Zacks
REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.
Zacks
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.
Zacks
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.
Zacks
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View
Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.
Zacks
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.
Zacks

Advertisement|Remove ads.